Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Lymphocytes with Nivolumab and Cytarabine in Older AML
NCT03381118Phase 2Terminated
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Disease-free survival at 2 years. Started Jun 2017; status: terminated.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03381118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381118.